All In Biotech

Drug Trial Radar · NCT05349617

Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years

A Phase 3 Safety and Immunogenicity Trial of the VLP-Based Chikungunya Virus Vaccine PXVX0317 in Adults ≥65 Years of Age

Last checked: Nov 20, 2026Latest source record: Dec 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 413 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

413

Actual

Start

May 12, 2022

Primary completion

Jun 19, 2023

Study completion Aug 8, 2023

Sponsor

Lead sponsor
Bavarian NordicIndustry
Sponsor type
Industry
Collaborators
Emergent BioSolutions
First posted
Apr 27, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this phase 3, randomized, double-blind, placebo-controlled study is to evaluate the safety and immunogenicity to PXVX0317 in adults ≥65 years of age.

Conditions

  • Chikungunya Virus

Interventions

  • CHIKV VLP/adjuvantBiological

    PXVX0317 vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant

  • PlaceboBiological

    Placebo is comprised of formulation buffer

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Anti-CHIKV SNA Titer (NT80) Seroresponse Rates at Day 22 in Baseline Seronegative ParticipantsTime frame: 21 days postvaccination
  2. Anti-CHIKV SNA Titer (NT80) Geometric Mean Titers (GMT) at Day 22Time frame: 21 days postvaccination
  3. Incidence of Solicited Adverse Events (AE)Time frame: 7 days postvaccination
  4. Incidence of Unsolicited AEsTime frame: 28 days postvaccination
  5. Incidence of Serious Adverse Events (SAE)Time frame: 182 days postvaccination
  6. Incidence of Medically Attended Adverse Events (MAAE)Time frame: 182 days postvaccination
  7. Incidence of Adverse Events of Special Interest (AESI)Time frame: 182 days postvaccination

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Suncoast Research Associates, LLC

    Miami, Florida

  • Panax Clinical Research

    Miami Lakes, Florida

  • Global Clinical Research Professionals (GCP)

    St. Petersburg, Florida

  • AMR Kansas City

    Kansas City, Missouri

  • Rochester Clinical Research, Inc.

    Rochester, New York

  • Coastal Carolina Research Center

    North Charleston, South Carolina

  • DM Clinical Research CyFair

    Houston, Texas

  • BHFC Research

    San Antonio, Texas

  • DM Clinical Research Tomball

    Tomball, Texas

  • Spaulding Clinical

    West Bend, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.